New BSR Funding Opportunities for Behavioral and Social Scientists

BSR has recently published or joined the following new Requests for Applications (RFAs), Program Announcements (PARs), and Notices of Special Interest (NOSIs):

• RFA-AG-23-022 and RFA-AG-23-023: Measures and Methods for Research on Family Caregivers for People Living with Alzheimer’s Disease and Related Dementias invites R01 and R21 applications for the development of methods and measures for capturing expanded definitions of “family” and related concepts relevant to informal caregiving for people living with Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD), and for the implementation of these measures in new and existing studies.

  • NIA intends to commit $3,960,000 in fiscal year 2023 to fund up to 6 awards.

  • Applications are due October 20, 2022, with letters of intent due September 20, 2022.

  • Contact Dr. Amelia Karraker with questions.

  • For more information, here is the link to the FAQs.

• RFA-AG-23-024: Policy and AD/ADRD Healthcare Disparities: Access, Utilization, and Quality invites R01 applications to address variations (e.g., geographic, temporal) in social and health care policies to employ experimental, quasi-experimental, or other innovative approaches to uncover mechanisms driving disparities in care (i.e., access, utilization, and quality) for persons living with AD/ADRD.

  • NIA intends to commit $4,500,000 in FY2023 to fund 5-6 awards.

  • Applications are due October 20, 2022, with letters of intent due September 20, 2022.

  • Contact Dr. Elena Fazio with questions.

  • For more information, here is the link to the FAQs.

• RFA-AG-23-025: Alzheimer's-related Resource Centers for Minority Aging Research (AD/ADRD RCMAR) invites P30 applications from institutions proposing to develop, or renew, a Resource Center for Minority Aging Research (RCMAR) that focuses on behavioral and social science research in a key area related to Alzheimer’s disease (AD) and AD-related dementias (ADRD).

  • NIA intends to commit $6.4 million in FY2023 to fund 7-9 awards.

  • Applications are due October 21, 2022, with letters of intent due September 21, 2022.

  • Contact Dr. Melissa Gerald with questions.

• RFA-AG-23-026: Resource Centers for Minority Aging Research (RCMAR) invites P30 applications from institutions proposing to develop, or renew, a Resource Center for Minority Aging Research (RCMAR) that focuses on behavioral and social science research in a key area related to aging and/or to health disparities in older adults.

  • NIA intends to commit $4 million in FY2023 to fund 5-8 awards.

  • Applications are due October 21, 2022, with letters of intent due September 21, 2022.

  • Contact Dr. Melissa Gerald with questions.

• RFA-AG-23-027: Resource Centers for Minority Aging Research (RCMAR) Coordinating Center invites U24 applications that are proposing to develop and maintain a coordinating center (CC) for the Resource Centers for Minority Aging Research (RCMAR) program.

  • NIA intends to commit $800,000 in FY2023 to fund one award.

  • Applications are due October 21, 2022, with letters of intent due September 21, 2022.

  • Contact Dr. Melissa Gerald with questions.

• NOT-AG-22-025: Alzheimer’s-Focused Administrative Supplements for NIH Grants that are Not Focused on Alzheimer’s Disease requests applications to expand existing awards not currently focused on AD/ADRD to allow the research to develop such a focus.

  • Applications are due October 1, 2022.

  • Contact Dr. Rene Etcheberrigaray with questions and alert your BSR program officer if you plan to apply.

• RFA-AG-23-020: Building Infrastructure for Precision Medicine Research on Minority Health and Disparities in Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) promotes collaborative research programs to support the development of research infrastructure (e.g., tools, surveys, biospecimens, data, etc.) for precision medicine approaches for minority health and health disparities in AD/ADRD.

  • NIA intends to commit $2.8 million in fiscal year 2023 to fund five awards.

  • Applications are due October 22, 2022.

  • Contact Dr. Janine Simmons with questions.

• PAR-22-214: Geroscience Course funding opportunity solicits applications that propose to integrate education in basic, applied, translational, behavioral, and clinical geroscience research and supports short-term education programs, such as intensive summer institutes, seminar series, online courses, and advanced workshops on methodology.

  • Applications are due October 21, 2022.

• NOT-OD-22-166: Research on the Health of Bisexual and Bisexual + People solicits research, research training, and research career development on the health and well-being of people who identify as bisexual or bisexual+.

  • The first available due date is September 25, 2022.

  • Contact Dr. Melissa Gerald with questions.

• Additional Funding Opportunities with submission deadlines this fall. Visit our Funding Opportunities and Applicant Resources page or more information on opportunities related to Social Connectedness, Dyadic Interpersonal Processes, Climate Change, Violence, and other topics.

• NIA Concept Clearances may become future FOAs. We post them here after each Council meeting to give interested researchers maximal lead time to plan projects on topics such as:

  • Estimating the Monetary Costs of Dementia in the United States Using NIA Funded Datasets

  • Understanding the Supply of Professional Dementia Care Providers and Their Decisions

Supplement Awards to Link Big Data and the Impact of COVID-19 on People Living with Dementia

The NIA IMPACT Collaboratory has been awarded two COVID-19 Supplements partnering with major retail pharmacies to create a massive monitoring system of the long-term safety and efficacy of COVID-19 vaccination on people with AD/ADRD.

These two studies are: Monitoring Medicare Beneficiaries' Response to COVID vaccines (CVS Project) This project established an active post-vaccination surveillance system of a large population to track and report safety and outcomes related to SARS-CoV-2 vaccine(s). Working jointly with CVS Health and the Medicare & Medicaid Resource Information Center (MedRIC) at Acumen, LLC, the project established a data infrastructure to monitor the effects of COVID-19 vaccines administered to Medicare beneficiaries by CVS across the country. Data transfers from the national retail pharmacy chain are merged with Medicare data. The resulting data base is analyzed to identify demographic, race/ethnicity, clinical (e.g., ADRD), and health care system factors associated with being vaccinated, estimate the rate of adverse events attributable to the vaccine and estimate breakthrough COVID illness among vaccinated Medicare beneficiaries. This program provides the basis for assessing mid- to long-term safety and efficacy of the different vaccines being distributed for use in the elderly population in the country. Medicare Match for post-vaccination monitoring (Walgreens) This project builds on the researchers’ partnership with CVS to establish a data infrastructure to monitor the effects of COVID-19 vaccines administered to Medicare beneficiaries by CVS across the country. The goal of this project is to add data from Walgreen’s 13,231,175 million Medicare beneficiary pharmacy customers to the existing infrastructure which will increase the research team’s capacity to track immediate and long term effects of vaccination on nearly half the population of Medicare beneficiaries. The need for a larger study population is particularly important because those with ADRD already suffering from neurodegenerative diseases may be at greater risk of serious neurological adverse events of vaccines. In addition, the unknown potential for adverse events may result in high rates of incomplete vaccination (both shots) among older adults. Such uncertainty contributes to vaccine hesitancy and may result in large disparities in SARS-CoV-2 vaccination among racial/ethnic groups, for which disparities in seasonal influenza vaccination already exist. To learn more about these studies, visit this page on Building Infrastructure Supplement Awards, and the press release from Brown University at this link.

New York Regional Center for Diabetes Translation Research Pilot and Feasibility Program

The New York Regional Center for Diabetes Translation Research (NY-CDTR) announces the availability of Pilot and Feasibility (P&F) funding for preliminary studies to support planned extramural funding applications (NIH preferred) for diabetes-related translational research. Secondary analyses of existing, pertinent large data sets, which can lead to external funding, are a priority. Budget requests can be up to $50,000/year for one-year grant proposals, or up to $25,000/year for 2 years. For 2021-2022, meritorious proposals for $50,000/year for 2 years will also be considered, with a maximum of one award being granted. A 2nd year of funding is always contingent on progress and available program funding. Proposals should use translational research methods such as: implementation or dissemination science, natural experiment methods, as well as quantitative or qualitative methods to investigate how to improve diabetes prevention or care and outcomes at the individual, group, health system or population level. Applications involving research in diabetes/obesity across the life span, population health, health systems, or natural experiments are strongly encouraged. Translation research focused on Latinos/Hispanics, health disparities, and social determinants of health is of particular interest. P&F funds may supplement ongoing funded research projects (e.g., K awards), but non-overlap must be clearly demonstrated in the proposal. The NY-CDTR website (www.nycdtr.org) provides information re: core resources and services available to awardees to support their pilot study. ELIGIBILITY: Must hold the rank of Assistant Professor (or equivalent) or higher at the time of the award. This program is designed to support (in order of priority): 1) New investigators, early stage investigators (ESIs), and under-represented minority investigators (URMiR) with interests in diabetes and/or obesity. In this category are investigators shifting from mentor-based research to an independent career. Meritorious proposals from these investigators receive the highest priority for funding. 2) Established investigators, in other research areas or cross-disciplinary research, who wish to apply their expertise to diabetes or obesity. High-risk, high-reward proposals receive priority. 3) NY-CDTR members who wish to explore a new area of innovative research that constitutes a substantive departure from their previous or ongoing externally funded diabetes research.

View funding announcement